Trials / Completed
CompletedNCT05522439
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Pharmacodynamic, Efficacy and Safety of Multiple Subcutaneous Injections of SHR-1703 in Asthma Patients With Eosinophil Phenotype
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1703 | SHR-1703 will be administered by SC injection. |
| DRUG | SHR-1703 Placebo | Matching Placebo will be administered by the SC route. |
Timeline
- Start date
- 2022-12-22
- Primary completion
- 2024-09-12
- Completion
- 2024-09-12
- First posted
- 2022-08-31
- Last updated
- 2025-05-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05522439. Inclusion in this directory is not an endorsement.